• Vaccine Name: Herpes simplex virus type 2 DNA vaccine encoding GB
• Target Pathogen: Herpes simplex virus type 1 and 2
• Target Disease: Herpes
• Vaccine Ontology ID: VO_0011406
• Type: DNA vaccine
• Status: Research
• Antigen: Herpes simplex virus type 2 glycoprotein B (UL27)
• UL27 gene engineering:
  • Type: DNA vaccine construction
  • Description: The plasmid DNA used for immunization was purified by polyethylene glycol precipitation. Briefly, the cellular proteins were precipitated with 1 volume of 7.5 M ammonium acetate. The supernatant was then precipitated with isopropanol, after which the plasmids were extracted three times with phenol-chloroform and then precipitated with pure ethanol. The DNA quality was then checked by electrophoresis in 1% agarose gel. Next, the concentration of the plasmid DNA was measured using a GeneQuant RNA/DNA calculator (Biochrom, Cambridge, UK). The amount of endotoxin was then determined using the Limulus amebocyte lysate (LAL) test (< 0.05 EU/µg) (Kim et al., 2009).
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0000212
• Immunization Route: Intranasal

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Groups of 5- to 6-week old female mice (n = 7) were co-immunized intranasally (i.n.) with 100 µg of pCIgB in the presence of β2-adrenergic agonist, salbutamol (10, 50, 100, and 200 µg). To examine the effect of plasmid DNA backbone (e.g. CpG motif), some of mice were immunized i.n. with 100 µg of the control vector (pCI-neo) in parallel. The i.n. immunization was performed three times at 7-day intervals (days 0, 7, and 14) by depositing pCIgB dissolved in a total volume of 20 µl of PBS (pH 7.2) containing the indicated dose of salbutamol onto the nares of deeply anesthetized mice (Kim et al., 2009).
• Challenge Protocol: BALB/c mice were subcutaneously injected with Depo-Provera (DP) (Upjohn Co., Kalamazoo, MI) at 2 mg per mouse. Five days following the injection of DP, the mice were challenged intravaginally with 10^6 PFU of HSV-1 McKrae. The mice were examined daily for vaginal inflammation, neurological illness, and death (Kim et al., 2009).
• Efficacy: The present study evaluated the modulatory functions of salbutamol co-administered with DNA vaccine expressing gB (UL27) of herpes simplex virus (HSV) via intranasal (i.n.) route. The enhanced immune responses caused by co-administration of salbutamol provided effective and rapid responses to HSV mucosal challenge, thereby conferring prolonged survival and reduced inflammation against viral infection (Kim et al., 2009).